Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X:

“Our collaborative effort to characterize MET kinase domain mutations as novel & targetable alterations in NSCLC and other cancer types is out in Cancer Discovery! Led by scientists Federica Pecci & Seshiru Nakazawa.

Using comprehensive genomic profiling among >600,000 patients, we identified MET TKD mutations as putative oncogenic driver across diverse cancers, with a frequency of ~0.5%. The most frequent included substitutions at positions H1094, L1195, F1200, D1228 & Y1230.

Preclinical modeling of these alterations demonstrated their oncogenic potential & differential patterns of sensitivity to type I and II MET inhibitors. 2 patients with metastatic NSCLC harboring H1094Y and F1200I mutations had partial responses to a type I MET inhibitor.

In summary, activating MET TKD mutations occur in multiple malignancies and may confer clinical sensitivity to currently available MET inhibitors. This study highlights the importance of performing comprehensive genomic tumor profiling to detect rare but targetable drivers.”

Read the article.
Source: Biagio Ricciuti/X